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Abstract
Background:  Insulinoma is the most common endocrine tumor of the pancreas. Accurate
preoperative detection and localization of insulinomas is essential for the appropriate selection of
candidates for surgery. We present two cases with benign pancreatic insulinoma.
Case presentation: Preoperative evaluation for patients with suspected insulinomas has been
controversial. Endoscopic ultrasonography (EUS) has a sensitivity of 95% in well skilled operators
and well tolerated preoperative imaging method.
Conclusion: We have detected the insulinomas with EUS before surgery in our patients but other
imaging modalities did not help us for localization of them. Patients have been asymptomatic
postoperatively with no hypoglycemia on repeat fasting. We reviewed here the different modalities
for preoperative localization of insulinoma.
Background
Insulinoma is a neuroendocrine tumour derived mainly
from the pancreatic islet cells producing excessive
amounts of insulin. Insulinoma is the most common
form of the pancreas islet cell tumors (60%). It can be
seen at every age but mostly seen in females above age 50
years old [1,2]. Ninety percent of all cases are benign, sol-
itary and located in pancreas. In adults 90% of solitary
lesions are smaller than 2 cm, and 30% are smaller than 1
cm in size. Small amount of cases (10%) can be found
malignant and multiple. Because of nonspecific symp-
toms 20% of cases are misdiagnosed primarily. Major
symptoms and signs are related to hypoglycemia and
become significant due to exercise and fasting. Insuli-
noma is diagnosed with he elevated (or non-suppressed)
insulin levels when hypoglycemia occurred [3].
In cases that were clinically suspected for insulinoma, C-
peptide suppression test or prolonged supervised fast tests
are used for diagnosis. In these cases, suspected tumor
localization has been done with different laboratory and
scanning procedures. Because they are small tumors the
sensitivity of transabdominal ultrasonography (TAUSG)
and abdominal computerized tomography (CT) scanning
are low (between 23–63% and 40–73% respectively).
Angiography and transhepatic venography have higher
sensitivity rates (60–98%) but they are expensive and
invasive procedures [2]. Endoscopic ultrasonography
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(EUS) has a sensitivity of 95% in well skilled operators.
Intraoperative ultrasonography (IOUSG) is a well diag-
nostic era with high sensitivity (90%) but it is difficult to
do and it needs pancreatic mobilization and this can
cause splenic vein trauma [4]. In this manuscript, we men-
tion two insulinoma cases that were diagnosed in six
months period.
Case 1
A 43 years old female patient defines hypoglycemic
attacks for two years. In physical examination the body
mass index (BMI) was 27 kg/m2, initial glucose level was
48 mg/dl (70–11 mg/dl), plasma insulin level was 16
μIU/ml (5–25 μIU/ml), C-peptide level was 2.7 ng/ml
(1.6–3.6 ng/ml). Prolonged supervised fast test was
applied and at the sixteenth hour of the test hypoglycemic
symptoms were occurred. Simultaneously taken blood
samples showed the glucose 23 mg/dl, plasma insulin
12.7 μIU/ml, insulin/glucose ratio was 0.52. The TAUSG
and CT scan showed no pathology. In the EUS scanning at
the pancreas uncinate process, there was a hypoechoic 13
mm nodular lesion (Figure 1). It was in homogenous
echo and well shaped. It was toughed as neuroendocrine
tumor. She was examined for multiple endocrine neopla-
sia. Magnetic resonance imaging (MRI) of hypophysis,
hypophysial hormonal analysis and intact parathormone
levels were normal. She was scheduled for surgical opera-
tion and preoperatively fluid therapy with dextrose in
water and 50 μg (tid) octreotide was applied subcutane-
ously. In the surgical operation the tumor was found at
the localization defined by EUS and enucleation proce-
dure was applied. In the histopathologic examination the
specimen showed positive staining for insulin and it was
in 15 × 11 × 8 mm in size. The glucose and insulin levels
were normal at postoperative period.
Case 2
A 62 years old female patient defines hypoglycemic
attacks for 1.5 years. In physical examination the body
mass index (BMI) was 24 kg/m2, initial glucose level was
41 mg/dl (70-1-mg/dl), plasma insulin level was 17 μIU/
ml (5–25 μIU/ml), C-peptide level was 12.9 ng/ml (1.6–
3.6 ng/ml). Prolonged supervised fast test was applied
and at the sixth hour of the test hypoglycemic symptoms
were occurred. Simultaneously taken blood samples
showed the glucose 28 mg/dl, plasma insulin 28.1 μIU/
ml, insulin/glucose ratio was 1. The TAUSG and CT scan
showed no pathology. In the EUS scanning at the pan-
creas uncinate process, there was a hypoechoic 11 mm
nodular lesion (Figure 2). It was in homogenous echo and
well shaped. It was toughed as neuroendocrine tumor.
She was examined for multiple endocrine neoplasia. Mag-
netic resonance imaging (MRI) of hypophysis, hypophy-
sial hormonal analysis and intact parathormone levels
were normal. She was scheduled for surgical operation
and preoperatively fluid therapy with dextrose in water
and 50 μg (tid) octreotide was applied subcutaneously. In
the surgical operation the tumor was found at the locali-
zation defined by EUS and enucleation procedure was
applied. In the histopathologic examination the specimen
showed positive staining for insulin and it was in 9 × 9 ×
8 mm in size. The glucose and insulin levels were normal
at postoperative period.
Discussion
Diagnosis of insulinoma may delay because symptoms
are nonspecific. Sometimes neuroglycopenic symptoms
are chiefly seen in patients and these groups of patient are
misdiagnosed as epilepsy or neuropsychiatric disease. In
patients with insulinoma, diplopia, sweating, palpitation
is seen at a rate of 85%; confusion or abnormal behavior
In the EUS scanning at the pancreas uncinate process, hypoe- choic 13 mm nodular lesion Figure 1
In the EUS scanning at the pancreas uncinate proc-
ess, hypoechoic 13 mm nodular lesion.
In the EUS scanning at the pancreas uncinate process, hypoe- choic 11 mm nodular lesion Figure 2
In the EUS scanning at the pancreas uncinate proc-
ess, hypoechoic 11 mm nodular lesion.Cases Journal 2008, 1:362 http://www.casesjournal.com/content/1/1/362
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80%; unconsciousness and amnesia 53% and epilepsy
12% [1]. In our cases the major symptoms were sweating,
palpitation, tremor and transient unconsciousness. One
of them had misdiagnosed as epilepsy previously by neu-
rology clinic. In both cases duration of symptoms was
more than one year before diagnosis. Hypoglycemia was
mostly seen after exercise and prolonged fasting. In insuli-
noma cases no other signs or symptoms can be found
except hypoglycemic symptoms and obesity. Approxi-
mately 25% of cases are overweight because of the hyper-
alimentation due to hypoglycemic symptoms [5]. One of
our cases was over weight and the other had a normal BMI
value.
It is diagnosed with hypoglycemic symptoms and
hypoglycemia and hyperinsulinism simultaneously. If the
blood glucose level is under 40 mg/dl and the insulin
level is over 6 μIU/ml, it is diagnosed as hypoglycemia
due to hyperinsulinism [5]. If it is suspected of exogenous
insulin use, C-peptide levels will be helpful in diagnosis.
High levels of C-peptide mark the endogenous insulin
secretion. Some different tests can be used in order to
show inadequate insulin secretion in cases that are sus-
pected as insulinoma. C-peptide suppression test and pro-
longed supervised fast tests are two of these tests [3].
80–90% of insulinomas are solid and benign. However
they localize on corpus and head mostly, they rarely local-
ize ectopically on pancreas 5–10% of cases are with mul-
tiple endocrine neoplasia type I (MEN I) and in this cases
the adenomas are generally multiple [1]. The diameter in
90% cases is smaller than 2 cm, in 50% smaller than 1.3
cm, in 30% smaller than 1 cm [6]. One of the research on
30 insulinoma cases has reported that 11 of the their cases
were localized on the tail of the pancreas, 6 of their cases
were localized on the uncinate process, 6 were on the cor-
pus, 5 were on the head, 2 were on the neck and the
dimensions of the adenomas were about 4 – 30 mm (aver-
age 13 mm) [7]. Both of our cases had adenoma on unci-
nate process and the dimensions were smaller than 15
mm and no other clinical or laboratory abnormalities for
MEN I suspicion.
A USG, CT, EUS, percutaneous transhepatic portal vein
sampling (PTPVS), selective intra-arterial pancreatic stim-
ulation (SIAPS), and also somatostatin receptor scintigra-
phy (SRS) have been used for tumor localization. But any
of the procedures have enough sensitivity. Some of the
investigators believe that when insulinoma diagnose clin-
ically and biochemically there is no need to preoperative
imaging because most of the lesions were located on pan-
creas and dimensions were small and also IOUSG and
palpation procedures were enough for localization [8].
The localization of the adenoma was important for the
decision of surgical strategy and also suggesting to ignore
of the nesidioblastosis which is the cause of hypoglycemia
by islet cell hyperplasia.
The sensitivity of USG on insulinoma patients were about
29 – 63% because of small dimensions of the tumor and
also the fatness of patients as well. In both cases which we
underwent, there was no adenoma on pancreas showed in
T A U S G,  C T  i s  a  k i n d  of  t e c h n i qu e  t h a t  c a n de t e r m i ne
tumors which are smaller than 1 cm and it is told its' sen-
sitivity is about 40–73% also [2]. Recently it is told that
the adenomas that can not be showed with any other tech-
niques could determine some new techniques like dual
phase helical CT [9]. The superiority of dual phase helical
CT to dynamic sequential scan is the permutation of
removing the sequence skipping due to uncooperation of
breath-phase and screening of lesion in arterial phase,
also. The reason of that is scanning of the pancreas in a
breath interval.
Our two cases were underwent CT. Although one of the
adenomas diameter was 15 mm – that can be measured
by CT – no adenomas were showed in CT anyway. Tumors
can be determined with well skilled operators 80 – 90%
by EUS [10]. This method is much more successful in
tumors which are located in the head of pancreas than
located on the tail of the pancreas. EUS imaging chance
was found very low on pancreas corpus or tail tumors
which are smaller than 1 cm [11]. The advantages of EUS
is high frequency resolutions, the very close determina-
tion chance to pancreas and elimination of air and bone
images. In our two cases the adenomas diagnosed by EUS
also.
The localization of adenoma can be determined by meas-
uring the hormones from the branches of portal veins in
PTPVS. The diagnostic value is about 60–98%. One of the
other techniques is SIAPS. The technique can be explained
measuring of hormone from synchronize venous catheter
after injection calcium to arterials which are feeding pan-
creas. Diagnostic value is 90% [12]. Neither TPVS nor
SIAPS were used frequently as they are both invasive. As
the pancreatic tumors contain so much somatostatin
receptors, SRS can be used in diagnose which has 60%
sensitivity [13]. SRS is much successful in determining of
metastatic tumors than in primer tumors and it indicates
that octreotide therapy can be useful in positive cases [14].
In our cases we did not carry out SRS.
IOUSG's sensitivity is about 75–90%. IOUSG and palpa-
tion are complementary techniques. Gouyo et al reported
that they have diagnosed the tumors 62.5% with inspec-
tion and 96.4% with palpation and also they have
reported that 20 of 21 patients diagnosed by IOUSG [10].
IOUSG method is especially successful in cases which arePublish with BioMed Central    and   every 
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not located preoperatively. Because of our cases were diag-
nosed preoperatively, we did not carry out IOUSG.
Surgery is recommended therapy in insulinomas as the
tumors are often soliter and related to benign adenomas.
For small and benign characteristic adenomas enucleation
is enough and distal pancreatectomy may be suitable for
the lesions which are located on the corpus and on the tail
of the pancreas. Distal pancreatectomy is suggested for the
lesions which can not diagnose by palpation and IOUSG.
Total pancreatectomy is suggested for the malign, multi-
ple and large tumors. But medical treatment is suggested
when there is contraindication for surgery and in uncon-
trolled preoperative hypoglycemia. Streptozocin, Diazox-
ide, Verapamil, Pheytoin, somatostatin can be used for
the medical treatment [15].
Both of our cases underwent enucleation. Adenomas have
been detected in histopathologic analysis. And both cases
were underwent 50 μg (tid) subcutan octreotide treat-
ment.
When EUS is applied by well skilled operators, it can help
the chosen operation type as well as there will be no need
invasive diagnostic methods. And also intraoperative pal-
pation must be done carefully. However insulinomas
localization were pancreas and the tail part of pancreas,
they can be diagnosed any other parts of pancreas during
the operation. So palpation is much important in these
situations. Our findings indicate that a diagnosis can be
suggested by biochemical evaluation, clinical symptoms
and by EUS.
If there is only one small adenoma enucleation is the most
effective method. In this situation complications like dia-
betes mellitus and exocrine pancreas function disorders
can be seen so rarely.
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